Astrazeneca PLC (AZN) — 6-K Filings

All 6-K filings from Astrazeneca PLC. Browse 49 Foreign Current Report reports with AI-powered summaries and risk analysis.

6-K Filings (49)

AstraZeneca's Tezepelumab Shows Positive Phase III COPD Results — Apr 20, 2026 Risk: low
AstraZeneca PLC announced positive Phase III results for its COPD treatment, tezepelumab, on April 20, 2026. The trial met its primary endpoint, demonstrating a
AstraZeneca PLC Reports AGM Results — Apr 9, 2026 Risk: low
AstraZeneca PLC filed a Form 6-K on April 9, 2026, reporting the results of its Annual General Meeting (AGM). The filing details the outcomes of resolutions vot
AstraZeneca's Liver Cancer Drug Combo Shows Improved PFS — Apr 2, 2026 Risk: low
On April 2, 2026, AstraZeneca PLC filed a Form 6-K reporting that their IMFINZI and IMJUDO combination therapy has shown improved progression-free survival (PFS
AstraZeneca PLC Files 6-K on Voting Rights — Apr 1, 2026 Risk: low
On April 1, 2026, AstraZeneca PLC filed a Form 6-K with the SEC, reporting its total voting rights and the admission of shares. The filing provides details on t
AstraZeneca's IMFINZI Shows Positive Phase III Lung Cancer Results — Mar 31, 2026 Risk: low
AstraZeneca PLC announced on March 31, 2026, that its IMFINZI (durvalumab) in combination with chemotherapy demonstrated positive results in the Phase III ALTA-
6-K Filing — Dec 22, 2025
6-K Filing — Dec 19, 2025
Enhertu Gets US Approval for 1st-Line HER2+ Breast Cancer — Dec 16, 2025 Risk: low
AstraZeneca PLC announced on December 16, 2025, that its drug Enhertu has received US approval for first-line treatment of HER2-positive metastatic breast cance
AstraZeneca PLC Files 6-K Report — Dec 4, 2025 Risk: low
AstraZeneca PLC filed a Form 6-K on December 4, 2025, reporting its status as a foreign issuer. The filing indicates that AstraZeneca is submitting its reports
AstraZeneca PLC Files 6-K Report — Dec 1, 2025 Risk: low
AstraZeneca PLC filed a Form 6-K on December 1, 2025, reporting as a foreign issuer. The filing indicates that the company is submitting its report under the 19
AstraZeneca's Imfinzi Approved for Early Gastric Cancer in US — Nov 26, 2025 Risk: low
AstraZeneca PLC announced on November 26, 2025, that its drug Imfinzi has received US approval for the treatment of early-stage gastric cancer. This approval ma
AstraZeneca Announces Maryland Manufacturing Investment — Nov 24, 2025 Risk: low
AstraZeneca PLC announced a manufacturing investment in Maryland, USA, on November 24, 2025. The company, headquartered in Cambridge, UK, is filing a Form 6-K r
AstraZeneca's Koselugo Approved in US — Nov 20, 2025 Risk: low
AstraZeneca PLC announced on November 20, 2025, that Koselugo (selumeticinib) has been approved in the US. This marks a significant milestone for the company's
6-K Filing — Nov 17, 2025
6-K Filing — Nov 14, 2025
AstraZeneca PLC Files Director Shareholding Report — Nov 10, 2025 Risk: low
AstraZeneca PLC filed a Form 6-K on November 10, 2025, reporting its shareholdings for Directors and Persons Disclosing Managerial Responsibilities (PDMRs). Thi
AstraZeneca PLC Files 9M and Q3 2025 Results — Nov 6, 2025 Risk: low
AstraZeneca PLC filed a Form 6-K on November 6, 2025, reporting its 9-month and Q3 2025 results. The filing is a report of a foreign issuer and indicates that A
6-K Filing — Nov 3, 2025
AstraZeneca PLC Files November 2025 6-K Report — Nov 3, 2025 Risk: low
AstraZeneca PLC filed a Form 6-K on November 3, 2025, reporting as a foreign issuer. The filing is for the month of November 2025 and indicates the company file
AstraZeneca's Koselugo Approved in EU for NF1 — Oct 28, 2025 Risk: low
AstraZeneca PLC announced on October 28, 2025, that Koselugo (selumeticinib) has received approval in the European Union. This approval is for the treatment of
Tezspire Approved in EU for CRSwNP — Oct 22, 2025 Risk: low
AstraZeneca PLC announced on October 22, 2025, that Tezspire has received European Union approval for the treatment of Chronic Rhinosinusitis with Nasal Polyps
AstraZeneca's SAPHNELO gets positive EU opinion — Oct 20, 2025 Risk: low
AstraZeneca PLC announced on October 20, 2025, that it received a positive opinion from the European Medicines Agency's Committee for Medicinal Products for Hum
AstraZeneca Agrees to Lower US Medicine Prices — Oct 14, 2025 Risk: medium
AstraZeneca PLC filed a Form 6-K on October 14, 2025, reporting an agreement with the US Government to lower medicine prices. This filing is made pursuant to Ru
AstraZeneca's BAXDROSTAT Trial Meets Primary Endpoint — Oct 7, 2025 Risk: low
AstraZeneca PLC announced on October 7, 2025, that its BAXDROSTAT Phase 3 trial, BAX24, met its primary endpoint. The trial evaluated BAXDROSTAT for the treatme
AstraZeneca's Dato-DXd Shows Improved Survival in Breast Cancer Trial — Oct 6, 2025 Risk: medium
AstraZeneca PLC filed a Form 6-K on October 6, 2025, reporting on the TROPION-Breast02 trial. The filing indicates improved overall survival (OS) and progressio
AstraZeneca PLC Files 6-K Report — Oct 1, 2025 Risk: low
AstraZeneca PLC filed a Form 6-K on October 1, 2025, reporting as a foreign issuer. The filing indicates that AstraZeneca is submitting its reports under Form 2
AstraZeneca Harmonizes Listing Structure — Sep 29, 2025 Risk: low
AstraZeneca PLC announced on September 29, 2025, that it is harmonizing its listing structure. This move aims to simplify its corporate structure and enhance it
AstraZeneca PLC Files 6-K Report — Sep 29, 2025 Risk: low
AstraZeneca PLC filed a Form 6-K on September 29, 2025, to report information as a foreign private issuer. The filing indicates that AstraZeneca is required to
AstraZeneca PLC Files 6-K Shareholding Report — Sep 25, 2025 Risk: low
AstraZeneca PLC filed a Form 6-K on September 25, 2025, reporting its shareholding information as required for foreign issuers. The filing indicates the company
AstraZeneca's Tezspire gets EU nod for nasal polyps — Sep 22, 2025 Risk: low
AstraZeneca PLC announced on September 22, 2025, that their drug Tezspire has been recommended for approval in the European Union for the treatment of severe un
AstraZeneca's RESOLUTE Trial Meets Primary Endpoint — Sep 17, 2025 Risk: medium
AstraZeneca PLC announced an update on its RESOLUTE Phase III trial for its investigational medicine, Zynyz (retifanlimab-dlwr), in combination with chemotherap
AstraZeneca Files Routine 6-K Report — Sep 2, 2025 Risk: low
AstraZeneca PLC filed a Form 6-K on September 2, 2025, reporting for the month of September 2025. The company, registered under SEC file number 001-11960, is a
AstraZeneca PLC Files 6-K Report — Aug 28, 2025 Risk: low
AstraZeneca PLC filed a Form 6-K on August 28, 2025, reporting its status as a foreign issuer. The company, formerly known as ZENECA GROUP PLC until April 22, 1
AstraZeneca PLC Files Form 6-K — Aug 26, 2025 Risk: low
AstraZeneca PLC filed a Form 6-K on August 26, 2025, reporting its status as a foreign issuer. The filing confirms AstraZeneca PLC's principal executive offices
AstraZeneca PLC Files Form 6-K — Aug 21, 2025 Risk: low
AstraZeneca PLC filed a Form 6-K on August 21, 2025, reporting its status as a foreign issuer. The filing indicates that AstraZeneca is submitting its reports u
AstraZeneca PLC Files 6-K for Director Shareholding — Aug 18, 2025 Risk: low
AstraZeneca PLC filed a Form 6-K on August 18, 2025, reporting its shareholding information for Directors and PDMRs (Persons Discharging Managerial Responsibili
AstraZeneca PLC Files Form 6-K — Aug 15, 2025 Risk: low
AstraZeneca PLC filed a Form 6-K on August 15, 2025, reporting its status as a foreign issuer. The filing confirms that AstraZeneca is submitting its annual rep
AstraZeneca PLC Files 6-K Report — Aug 12, 2025 Risk: low
AstraZeneca PLC filed a Form 6-K on August 12, 2025, reporting its status as a foreign issuer. The filing confirms that AstraZeneca is submitting its annual rep
AstraZeneca PLC Files Form 6-K for August 2025 — Aug 1, 2025 Risk: low
AstraZeneca PLC filed a Form 6-K on August 1, 2025, reporting for the month of August 2025. The company, previously known as ZENECA GROUP PLC until April 22, 19
AstraZeneca PLC Files 6-K for Q2 2025 — Jul 29, 2025 Risk: low
AstraZeneca PLC filed a 6-K report on July 29, 2025, for the period ending June 30, 2025. The filing includes information related to various product segments su
AstraZeneca's Gefulimab Nanobody Hits Phase III Endpoints — Jul 24, 2025 Risk: low
AstraZeneca PLC announced on July 24, 2025, that its Gefulimab nanobody met the primary endpoints in a Phase III trial. The trial evaluated Gefulilimab in combi
AstraZeneca to Invest $50 Billion in US — Jul 22, 2025 Risk: low
AstraZeneca PLC announced plans to invest $50 billion in the United States over the next 10 years, focusing on research and development, manufacturing, and expa
AstraZeneca Updates on AL Amyloidosis Drug Anselamimab — Jul 16, 2025 Risk: low
AstraZeneca PLC announced an update on its investigational drug anselamimab for AL amyloidosis on July 16, 2025. The company is providing this information as pa
AstraZeneca's BAXdrostat Meets Primary Endpoint in Phase III Trial — Jul 14, 2025 Risk: low
AstraZeneca PLC announced on July 14, 2025, that its investigational medicine BAXdrostat met the primary endpoint in the BAXHTN Phase III trial. The trial evalu
AstraZeneca's Imfinzi gets EU approval for Stage III NSCLC — Jul 7, 2025 Risk: low
AstraZeneca PLC announced on July 7, 2025, that its Imfinzi drug has received approval in the European Union for the treatment of adult patients with unresectab
AstraZeneca PLC Files July 2025 6-K Report — Jul 1, 2025 Risk: low
AstraZeneca PLC filed a Form 6-K on July 1, 2025, reporting for the month of July 2025. The filing indicates that AstraZeneca is a foreign issuer and files annu
AstraZeneca's Datroway Approved in US for Lung Cancer — Jun 24, 2025 Risk: low
AstraZeneca PLC announced on June 24, 2025, that its drug Datopotamab deruxtecan (Datroway) has been approved in the US for the treatment of adult patients with
AstraZeneca Collaborates with CSPC — Jun 13, 2025 Risk: low
AstraZeneca PLC announced on June 13, 2025, that it has entered into a collaboration with CSPC. This partnership aims to advance the development of innovative m
AstraZeneca PLC Files 6-K on Director Shareholdings — Jun 12, 2025 Risk: low
AstraZeneca PLC filed a Form 6-K on June 12, 2025, reporting its shareholding information for Directors and Persons Discharging Managerial Responsibility (PDMRs

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX